scholarly journals Excellent survival, cancer type, and Nottingham grade after atypical lobular hyperplasia on initial breast biopsy

Cancer ◽  
2006 ◽  
Vol 107 (6) ◽  
pp. 1227-1233 ◽  
Author(s):  
Bernadette K. McLaren ◽  
Peggy A. Schuyler ◽  
Melinda E. Sanders ◽  
Roy A. Jensen ◽  
Jean F. Simpson ◽  
...  
Keyword(s):  
Breast Biopsy ◽  
Cancer Type ◽  
Atypical Lobular Hyperplasia ◽  
Nottingham Grade

The Significance of Atypical Lobular Hyperplasia at Percutaneous Breast Biopsy

2003 ◽  
Vol 9 (1) ◽  
pp. 10-12 ◽  
Author(s):  
Karen Dmytrasz ◽  
Paul Ian Tartter ◽  
Howard Mizrachy ◽  
Lynn Chinitz ◽  
Sharon Rosenbaum Smith ◽  
...  
Keyword(s):  
Breast Biopsy ◽  
Atypical Lobular Hyperplasia

scholarly journals Isolated Atypical Lobular Hyperplasia Diagnosed on Breast Biopsy: Low Upgrade Rate on Subsequent Excision With Long-Term Follow-up

2017 ◽  
Vol 142 (3) ◽  
pp. 391-395 ◽  
Author(s):  
Kristen E. Muller ◽  
Emily Roberts ◽  
Lili Zhao ◽  
Julie M. Jorns
Keyword(s):  
Breast Carcinoma ◽  
Carcinoma In Situ ◽  
Breast Biopsy ◽  
Ductal Carcinoma ◽  
Atypical Lobular Hyperplasia ◽  
Long Term Follow Up ◽  
History Of

Context.— The upgrade rate to carcinoma on excision for atypical lobular hyperplasia diagnosed on breast biopsy is controversial. Objective.— To review cases with isolated atypical lobular hyperplasia on biopsy to establish the rate of upgrade on excision and correlate with long-term follow-up. Design.— A database search was performed for 191 months to identify breast core biopsies with isolated atypical lobular hyperplasia. Cases with other atypical lesions in the biopsy or discordant radiologic-pathologic findings were excluded. Invasive carcinoma and ductal carcinoma in situ were considered upgraded pathology on excision. Patients without and with a history of, or concurrent diagnosis of, breast carcinoma were compared. Results.— Eighty-seven cases of isolated atypical lobular hyperplasia on biopsy underwent subsequent excision, which resulted in 3 upgraded cases (3.4%). All 3 cases with immediate upgrades revealed ductal carcinoma in situ. Upgrade was higher in patients with a concurrent diagnosis of breast carcinoma (2 of 26 and 1 of 61; 7.7% versus 1.6%, respectively). Follow-up information was available for 63 patients (57.8 ± 43.9 months; range, 6–183 months). Overall, 13% of patients without a history of breast carcinoma had a future breast cancer event, with the majority (83%) presenting in the contralateral breast. Conclusions.— With careful radiologic-pathologic correlation, the upgrade rate for isolated atypical lobular hyperplasia on biopsy is low, and a more conservative approach may be appropriate.

First experience with MRI-guided vacuum aspirated breast biopsy

2020 ◽  
pp. 25-31
Author(s):  
M. L. Mazo ◽  
O. E. Jacobs ◽  
O. S. Puchkova ◽  
M. V. Feldsherov ◽  
E. V. Kondratyev
Keyword(s):  
Breast Cancer ◽  
Breast Augmentation ◽  
Breast Biopsy ◽  
Breast Mri ◽  
Breast Tumors ◽  
High Tech ◽  
X Ray ◽  
Vacuum Aspiration ◽  
Mri Guided ◽  
Aesthetic Breast

The rate of detection of breast cancer by MRI, while other methods of radiological diagnosis are not sufficiently informative, ranges from 5.2 to 26.3 per cent. Suspicious breast tumors of category BI-RADS 4, 5 show morphological image-guided biopsy verification, in particular MRI with contrast. Purpose. To show the possibilities and features of carrying out MRI-guided vacuum breast biopsy, including after aesthetic breast augmentation. Material and methods. A comprehensive X-ray, ultrasound and MRI examination of 54 women aged between 28 and 70 years with different breast tumors was conducted. Of these, five were detected only by breast MRI with contrast, and were morphologically verified by MRI-guided vacuum aspiration biopsy. Results. 14 of the 54 patients with breast mass were diagnosed with breast cancer and 26 were diagnosed with benign diseases. The effectiveness of comprehensive examination and low-invasive high-tech MRI-guided procedures in early refined screening for breast cancer, including after aesthetic breast augmentation, has been demonstrated. MRI-guided vacuum-assisted breast biopsy is a fast, safe and accurate diagnostic method of morphological verification of suspicious breast tumors that do not have X-ray and ultrasound.

Concordant Versus Discordant Ultrasound Guided Breast Biopsy Results: How They Effect Patient Management?

2016 ◽  
Vol 01 (01) ◽  
Author(s):  
Imrana Masroor ◽  
Saira Naz Sufian ◽  
Shaista Afzal ◽  
Saba Sohail ◽  
Hafsa Qayyum
Keyword(s):  
Patient Management ◽  
Breast Biopsy ◽  
Ultrasound Guided

Small Molecular Leads Differentially Active Against HER2 Positive and Triple Negative Breast Cancer Cell Lines

2019 ◽  
Vol 15 (7) ◽  
pp. 738-742 ◽  
Author(s):  
Adnan Badran ◽  
Atia-tul-Wahab ◽  
Sharmeen Fayyaz ◽  
Elias Baydoun ◽  
Muhammad Iqbal Choudhary
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Cell Lines ◽  
Cancer Cell ◽  
Breast Cancer Cell ◽  
Triple Negative ◽  
Cancer Cell Lines ◽  
Breast Cancer Cell Lines ◽  
Cancer Type

Background:Breast cancer is the most prevalent cancer type in women globally. It is characterized by distinct subtypes depending on different gene expression patterns. Oncogene HER2 is expressed on the surface of cell and is responsible for cell growth regulation. Increase in HER2 receptor protein due to gene amplification, results in aggressive growth, and high metastasis in cancer cells.Methods:The current study evaluates and compares the anti-breast cancer effect of commercially available compounds against HER2 overexpressing BT-474, and triple negative MDA-MB-231 breast cancer cell lines.Results:Preliminary in vitro cell viability assays on these cell lines identified 6 lead molecules active against breast cancer. Convallatoxin (4), a steroidal lactone glycoside, showed the most potent activity with IC50 values of 0.63 ± 0.56, and 0.69 ± 0.59 µM against BT-474 and MDA-MB-231, respectively, whereas 4-[4-(Trifluoromethyl)-phenoxy] phenol (3) a phenol derivative, and Reserpine (5) an indole alkaloid selectively inhibited the growth of BT-474, and MDA-MB-231 breast cancer cells, respectively.Conclusion:These results exhibited the potential of small molecules in the treatment of HER2 amplified and triple negative breast cancers in vitro.

Sign in / Sign up

Export Citation Format

Share Document